Axiogenesis Cor.At mESC cardiomyocytes

Monday, 21 June, 2010 | Supplied by: Lonza Australia Pty Ltd


Online: www.lonza.com
Phone: 03 9550 0883
Msf249

Embryonic stem cell-derived cardiomyocytes have many of the phenotypic properties of primary cardiomyocytes and show great potential to model human diseases. The Cor.At cells are cardiomyocytes derived from transgenic mouse embryonic stem cells and are available cryopreserved in ampoules.

The cells are highly pure with ampoules containing 99% cardiomyocytes. Their minimal lot-to-lot variation is claimed to give consistent performance and the standardised production process ensures stable supply.

The cardiomyocytes are a good predictive model with relevant background including all important ion channels well characterised.

They are suitable for applications including: electrophysiology (patch clamp, microelectrode arrays, Ca2+ flux analysis), non-arrhythmic cardiotoxicity (cell viability, label-free analysis, troponin release), drug profiling and target discovery (hypertrophy, gene expression, transfection, tissue engineering).

Related Products

Cayman Chemical oxidative stress probes and spin traps

Cayman Chemical offers a comprehensive catalogue of reagents for oxidative stress research,...

Greiner Bio-One CELLSTAR Cell-Repellent Surface

Greiner Bio-One's surface technology inhibits cell adhesion, making the range suitable for...

Cerilliant Snap-N-Spike stable-labelled internal standards of antifungal agents

Cerilliant has introduced five stable-labelled internal standards of the antifungal agents...


  • All content Copyright © 2015 Westwick-Farrow Pty Ltd